No abstract available
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacology*
-
Biopsy
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / genetics
-
Carcinoma, Renal Cell / metabolism
-
Carcinoma, Renal Cell / secondary
-
Disease Progression
-
Drug Resistance, Neoplasm*
-
Heterozygote
-
Humans
-
In Situ Hybridization, Fluorescence
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / genetics
-
Kidney Neoplasms / metabolism
-
Kidney Neoplasms / pathology
-
Male
-
Methionine
-
Middle Aged
-
Point Mutation*
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-met / genetics*
-
Pyrazines / administration & dosage
-
Pyrazines / pharmacology*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Sequence Analysis, DNA
-
Threonine
-
Treatment Failure
-
Triazoles / administration & dosage
-
Triazoles / pharmacology*
Substances
-
2-(4-(3-quinolin-6-ylmethyl-3H-(1,2,3)triazolo(4,5-b)pyrazin-5-yl)pyrazol-1-yl)ethanol
-
Antineoplastic Agents
-
Pyrazines
-
Triazoles
-
Threonine
-
Methionine
-
Proto-Oncogene Proteins c-met
-
RON protein
-
Receptor Protein-Tyrosine Kinases
Associated data
-
ClinicalTrials.gov/NCT00706355